Rigel Optimistic On Fostamatinib Despite Narrow Phase III Benefit
Rigel's SYK inhibitor fostamatinib met the primary endpoint in the first of two pivotal Phase III trials in chronic ITP, but yielded a treatment effect in only 18% of the patients. CEO Raul Rodriguez discussed the data in an interview.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Rigel has its first US FDA approval for Tavalisse (fostamatinib) and plans to launch the drug for adults with immune thrombocytopenia (ITP) in late May, after working on the drug's development for more than a decade across multiple indications.
Rigel sees positive signs for Tavalisse in failed mid-stage study in autoimmune nephropathy, but investors don't share the optimism, sending the stock down almost 14% on the news.